论文部分内容阅读
目的:探讨抗人转铁蛋白受体(TfR)单克隆抗体(mAb)体外抗瘤效应。方法:采用CFSE染色、PI-AnnexinⅤ染色和PI染色,通过流式细胞术分析抗人TfR mAb对高表达的人肝癌细胞系HepG2和人乳腺癌细胞系MCF-7增殖、凋亡和周期的影响;通过MTT法检测抗人TfR mAb联合化疗药物对HepG2和MCF-7细胞增殖的抑制作用。结果:抗人TfRmAb能抑制HepG2和MCF-7细胞的增殖,并诱导其凋亡和S期阻滞;与化疗药物联用可增强其对肿瘤细胞增殖的抑制作用。结论:抗人TfR mAb具有良好的体外抗瘤效应。
Objective: To investigate the anti-tumor effect of anti-human transferrin receptor (TfR) monoclonal antibody (mAb) in vitro. Methods: The effects of anti-human TfR mAb on the proliferation, apoptosis and cycle of highly expressed human hepatoma cell line HepG2 and human breast cancer cell line MCF-7 were analyzed by CFSE staining, PI-Annexin Ⅴ staining and PI staining by flow cytometry The inhibitory effect of anti-human TfR mAb combined with chemotherapy drugs on the proliferation of HepG2 and MCF-7 cells was detected by MTT assay. Results: Anti-human TfRmAb could inhibit the proliferation of HepG2 and MCF-7 cells and induce apoptosis and S phase arrest. Combined with chemotherapeutic agents, the anti-human TfRmAb could inhibit the proliferation of HepG2 and MCF-7 cells. Conclusion: Anti-human TfR mAb has good anti-tumor effect in vitro.